NVIDIA (NVDA) on Monday said it is expanding its BioNeMo platform for AI-driven biology and drug discovery, unveiling new software models, data tools and partnerships aimed at linking artificial intelligence directly with laboratory experimentation.
The announcement follows Nvidia’s newly announced AI co-innovation lab with Eli Lilly, which the companies said will focus on applying large scale computing and AI models to drug discovery.
Nvidia also said it is working with Thermo Fisher Scientific to build autonomous laboratory infrastructure by embedding AI into scientific instruments. The companies aim to enable automated experiment design, execution and real-time data analysis, reducing the need for continuous human intervention in high-throughput research labs.
Nvidia also introduced new components to BioNeMo, including open models for RNA structure prediction and drug synthesis feasibility, GPU-accelerated cheminformatics tools and standardized workflows to train and deploy biological foundation models at scale.
The company said a growing group of biotech firms, AI drug developers and lab automation companies are adopting BioNeMo to connect digital “agentic” AI systems with physical laboratories, allowing experimental data to continuously feed back into model development.